AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 APR 14 - (NewsRx.com & NewsRx.net) -- Valentis Inc. (VLTS) has earned a milestone payment from Genencor International, Inc. (GCOR), which resulted from Genencor's initiation of subject dosing in a phase I clinical trial of its DNA-based therapeutic vaccine to treat hepatitis B.
A Valentis polymer delivery system, DNAVAX, was incorporated as a part of the Genencor therapeutic vaccine.
The Genencor Hepatitis B product is the second product to enter clinical testing that incorporates Valentis' DNAVAX vaccine delivery technology.
The DNAVAX technology has also been employed in an HIV product, which is currently in clinical development by Epimmune.
In an ...
Source: HighBeam Research, Therapeutics company earns milestone payment.